Gout Management Guidelines

Diagnosis and Monitoring

Serum uric acid (SUA) levels should be measured during symptom-free periods to avoid falsely lower levels during acute attacks, as SUA behaves as a negative acute phase reactant 1
Measuring SUA during acute attacks only may lead to underestimation of urate burden, as levels can be within normal range during attacks but elevated between attacks 1
Gout can be diagnosed by documenting the presence of monosodium urate (MSU) crystals from synovial fluid analysis, or by documenting classical clinical features such as podagra, presence of tophi, rapid response to colchicine, and characteristic imaging findings, as recommended by the American College of Rheumatology 2
A diagnosis of gout can also be made with two or more gout flares per year, presence of tophi, evidence of joint damage, urolithiasis, moderate-to-severe CKD (stage ≥3), or serum urate >9 mg/dL 3

The American College of Rheumatology strongly recommends initiating urate-lowering therapy (ULT) in patients with frequent gout flares (≥2 flares per year), presence of one or more subcutaneous tophi, or radiographic damage attributable to gout 3
The American College of Rheumatology conditionally recommends initiating ULT in patients with infrequent flares (<2/year) but with history of more than one flare, or with first flare and chronic kidney disease stage ≥3, SUA >9 mg/dL, or urolithiasis 3

The goal of ULT is to promote crystal dissolution and prevent crystal formation, with a target SUA below 6 mg/dL (360 μmol/L) for most patients with gout, and below 5 mg/dL (300 μmol/L) for patients with severe gout until clinical remission is achieved 4, 5, 6
Continue prophylaxis for more than 8 weeks when initiating ULT 7
The European League Against Rheumatism recommends measuring serum uric acid levels regularly, every 2-4 weeks during medication titration and every 6 months once the target is reached, to maintain target serum uric acid levels, with Grade A evidence 5, 6, 4

Low-dose colchicine, dosed at 0.6 mg once or twice daily, is most effective when started within 12 hours of symptom onset, and a loading dose of 1 mg followed 1 hour later by 0.5 mg on day 1 can be used for acute attacks 8
Corticosteroids, such as oral prednisolone 30-35 mg/day for 3-5 days, can be used for severe attacks, particularly with polyarticular involvement, and are preferred in elderly patients or those with contraindications to NSAIDs/colchicine 8
Febuxostat can be used as an alternative to allopurinol, starting at ≤40 mg/day and titration up to 80 mg daily as needed, and used with caution in patients with cardiovascular disease 3, 9, 6
Uricosuric agents (e.g., probenecid) can be used when xanthine oxidase inhibitors fail or are contraindicated, with a starting dose of 500 mg once or twice daily, and are less effective in patients with renal impairment (CrCl <50 ml/min) 3, 9, 6, 4
Combination therapy with allopurinol and a uricosuric agent can be used when monotherapy fails, as recommended by the European League Against Rheumatism with a strength of evidence level of 1A 6

Limit intake of purine-rich foods (e.g., red meat, organ meats, seafood) and moderate consumption of fructose-rich foods (e.g., orange and apple juice), and avoid sugar-sweetened beverages and limit alcohol consumption, especially beer and spirits, which significantly increases uric acid production 6, 4
Encourage low-fat dairy products, cherry consumption, and weight management through dietary intervention or bariatric surgery to reduce serum uric acid levels, and regular physical activity to decrease mortality associated with hyperuricemia 6
Regular exercise and adequate hydration are recommended, with a goal of increasing fluid intake to at least 2 liters daily and maintaining neutral or slightly alkaline urine to prevent stone formation, as recommended by the American College of Rheumatology and the European League Against Rheumatism 6, 4, 2, 10

Consider HLA-B*5801 testing in selected high-risk populations, such as Korean patients with stage 3 or worse CKD, and Han Chinese or Thai patients regardless of renal function, before initiating allopurinol 9
G6PD deficiency screening should be considered in patients of African American, Mediterranean, or Southeast Asian descent, especially if allopurinol is being used for tumor lysis syndrome management 11
Allopurinol can interact with medications such as azathioprine, 6-mercaptopurine, thiazide diuretics, and warfarin, highlighting the need for careful management of concomitant medications 12
Modifiable cardiovascular risk factors should be addressed as part of comprehensive gout management, as recommended by the European League Against Rheumatism 6
The American College of Rheumatology conditionally recommends switching from febuxostat to an alternative urate-lowering therapy in patients with a history of cardiovascular disease or new cardiovascular events 10